首页> 外文期刊>Trials >Radiotherapy-related skin toxicity (RAREST-02): A randomized trial testing the effect of a mobile application reminding head-and-neck cancer patients to perform skin care (reminder app) on radiation dermatitis
【24h】

Radiotherapy-related skin toxicity (RAREST-02): A randomized trial testing the effect of a mobile application reminding head-and-neck cancer patients to perform skin care (reminder app) on radiation dermatitis

机译:与放射疗法相关的皮肤毒性(RAREST-02):一种随机试验,测试移动应用提醒头颈癌症患者在放射性皮炎上进行护肤(提醒APP)的效果

获取原文
       

摘要

BACKGROUND:Radiotherapy of head-and-neck cancer can be associated with significant toxicities including dermatitis and oral mucositis. Severe toxicities may require interruptions of the radiation treatment associated with impairment of the patients' prognoses. This study will investigate whether the addition of a reminder app to standard care can reduce dermatitis and oral mucositis rates during radiotherapy in these patients.METHODS:This randomized trial compares standard care supported by a reminder app (Arm A) to standard care alone (Arm B) with respect to grade?≥?2 radiation dermatitis and oral mucositis at 60 Gy of radiotherapy, the minimum planned dose for patients receiving definitive or adjuvant radiotherapy for locally advanced head- and-neck cancer. Moreover, radiation-induced dermatitis and oral mucositis grade?≥?3 at 60 Gy and both grade?≥?2 and grade?≥?3 at the end of radiation treatment (EOT) will be evaluated, as well as quality of life and pain. According to sample size calculations, 80 patients are required per arm within the full analysis set. Taking into account that 5% of patients will not qualify for full analysis set, 168 patients should be randomized. The impact of the reminder app will be considered clinically relevant, if the rates of grade?≥?2 radiation dermatitis (primary endpoint) and oral mucositis (secondary endpoint) can be reduced by 20%.DISCUSSION:If the addition of a reminder app to standard care will lead to a significant reduction of radiation dermatitis and oral mucositis, it could become a helpful tool for patients with head-and-neck cancer during radiotherapy.TRIAL REGISTRATION:clinicaltrials.gov (NCT04110977). Registered on September 27, 2019. First patient is planned to be included in December 2019.
机译:背景:头颈癌的放射疗法可以与具有皮肤膜炎和口腔粘膜炎的显着毒性相关。严重的毒性可能需要与患者预期的损害有关的辐射治疗中断。本研究将调查添加提醒应用程序是否对标准护理进行了添加到这些患者的放疗过程中的皮炎和口腔粘液炎。方法:这种随机试验将提醒App(ARM A)支持的标准护理单独进行标准护理(ARM b)关于等级?≥?2辐射皮炎和60 GY的放射皮炎和口腔粘膜炎,用于接受局部晚期头部和颈部癌症的最终或佐剂放射治疗的患者的最低规划剂量。此外,辐射诱导的皮炎和口腔粘膜炎等级?≥≤3,在60 gy和均等?≥?2和辐射治疗结束时的≥2和等级?≥?3将进行评估,以及生活质量和质量疼痛。根据样本尺寸计算,每只ARM在完整分析集中需要80名患者。考虑到5%的患者不会有资格进行全分析套装,168名患者应随机分配。如果级别的速度Δ≥2放射性皮炎(初级终点)和口腔粘膜炎(辅助端点)可以减少20%,则提醒应用的影响将被视为临床相关性.Discussion:如果添加提醒应用程序标准护理将导致放射性皮炎和口腔粘膜炎的显着减少,它可能成为放射治疗期间头颈癌患者的有用工具.TIAL注册:CLINCOLTRIANS.GOV(NCT04110977)。 2019年9月27日注册。计划于2019年12月列入第一个患者。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号